2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-128433
    CK1-IN-3 349438-74-0 99.00%
    CK1-IN-3 (compound 51) is a AC1 inhibitor with an IC50s 2.22 µM for CK-1δ.
    CK1-IN-3
  • HY-128479
    JYL-273 1391826-17-7 98%
    JYL-273 is a TRPV1 agonist, with the IC50 of 361 nM in CHO-TRPV1 cell lines.
    JYL-273
  • HY-128783
    VU0090157 312622-77-8 98%
    VU0090157 is a positive allosteric modulator (PAM) of the M1 muscarinic acetylcholine receptor (mAChR). VU0090157 increases the affinity of ACh by binding to the allosteric site. VU0090157 can be used in the study of schizophrenia and Alzheimer's disease.
    VU0090157
  • HY-128794
    PF-05150122 1235406-00-4 98%
    PF-05150122 is a novel potent and selective human Nav1.7 channel blocker with the activity of inhibiting human pain signaling. PF-05150122 exhibited favorable biopharmacokinetic parameters in microdose studies, providing a basis for exploring its application in acute or chronic pain inhibition. The pharmacokinetic model of PF-05150122 predicted that at the corresponding oral dose, it could effectively reduce the 50% inhibitory concentration (IC50) of Nav1.7, demonstrating its inhibitory potential.
    PF-05150122
  • HY-12883B
    PF 05089771 tosylate 1430806-04-4 98%
    PF 05089771 tosylate is a potent, orally active and selective arylsulfonamide Nav1.7 inhibitor, with IC50 values of 11 nM, 12 nM, 13 nM, 171 nM and 8 nM for hNav1.7, cynNav1.7, dogNav1.7, ratNav1.7, and musNav1.7, respectively. PF 05089771 is under the study for pain and diabetic neuropathy.
    PF 05089771 tosylate
  • HY-128891
    Eperisone 64840-90-0 98%
    Eperisone ((±)-Eperisone) is an antispasmodic agent and centrally acting muscle relaxant useful in the study of diseases characterized by muscle stiffness and pain. Eperisone acts by relaxing skeletal and vascular smooth muscle, resulting in vasodilation, decreased muscle tone, improved circulation, and inhibition of pain reflexes. Eperisone is also a potent P2X7 receptor antagonist.
    Eperisone
  • HY-129049
    Vasotocin 9034-50-8 98%
    Vasotocin is the precursor of vasopressin. Vasotocin has functions including innervating the limbic–midbrain changes rapidly over evolutionary time in mediating various affiliative and reproductive behaviours. Vasotocin is important in the modulation of stress-related cognitive processes. Vasotocin administration facilitates the learning of a complex (agonistic) song pattern in the wild sparrow.
    Vasotocin
  • HY-129101
    (-)-Eseroline fumarate 70310-73-5 98%
    (-)-Eseroline fumarate is a metabolic of Physostigmine (HY-N6608), an AChE inhibitor. (-)-Eseroline fumarate elicits a leakage of lactic acid dehydrogenase (LDH) from cancer cells. (-)-Eseroline fumarate also induces the release of adenine nucleotides and 5-hydroxytryptamine (5-HT) from neuronal cells, thus induce cell death. (-)-Eseroline fumarate inhibits the electrically evoked twitches of the mouse vas deferens and of the guinea-pig ileum.
    (-)-Eseroline fumarate
  • HY-129237
    Azo-enkephalin 76995-89-6 98%
    Azo-enkephalin is an endorphin analog with significant analgesic activity. Azo-enkephalin can be used in the development of opioid analgesics.
    Azo-enkephalin
  • HY-129245
    Razobazam 78466-98-5 98%
    Razobazam (Hoe 175) is a benzodiazepine derivative with cognitive activity. Razobazam has been shown to improve learning performance in socially deprived rats. Razobazam increased avoidance scores by 18% after training. Razobazam caused significant changes in the optical density of certain areas of the rat brain, including a 22% decrease in the lateral habenula and a 25% increase in the ventral tegmental area. Razobazam also caused a 13% increase in optical density in the prefrontal cortex of rats.
    Razobazam
  • HY-129250
    AZD5213 1119807-02-1 98%
    AZD5213 is a selective and competitive human H3 receptor antagonist with a pKi value of 9.3 for hH3R. AZD5213 can be used for the research of sleep and cognitive regulation.
    AZD5213
  • HY-129278
    Lunarine 24185-51-1 98%
    Lunarine is an alkaloid, which can be isolated from the seeds of kale (Lunaria annua). Lunarine lowers the blood pressure, stimulates small intestinal motility, inhibits spontaneous contractions of uterus and nervous system, and exhibits an acute toxicity with LD50 of 62.3 mg/kg in dogs and rabbits. Lunarine exhibits antiparasitic activity through a competitive inhibition of protozoan oxidoreductase trypanothione reductase (TryR) with Ki of 304 μM.
    Lunarine
  • HY-129296
    YM-44781 free acid 173943-29-8 98%
    YM-44781 free acid is a non-peptide neuropeptide receptor antagonist with efficient NK(2) and NK(1) receptor antagonist activity. YM-44781 exhibits significant binding affinity on the NK(2) receptor (pKi = 9.94) and also on the NK(1) receptor Higher binding affinity (pKi = 9.09). In addition, YM-44781 also showed significant inhibitory effects on bladder contraction induced by selective NK(1) receptor agonists.
    YM-44781 free acid
  • HY-129305
    Tampramine fumarate 83166-18-1 98%
    Tampramine fumarate is a potent, selective, noncompetitive NE reuptake inhibitor. Tampramine fumarate has antidepressant activity. Tampramine fumarate can be used in research of depression.
    Tampramine fumarate
  • HY-129422
    Diallyl G 127808-81-5 98%
    Diallyl G is a delta-opioid receptor antagonist. Diallyl G shows inhibitory effect on GTPase.
    Diallyl G
  • HY-129449
    AnnH31 241809-12-1 99.91%
    AnnH31 is a Dyrk1A inhibitor (IC50: 81 nM). AnnH31 also inhibits MAO-A with an IC50 of 3.2 μM. AnnH31 inhibits cell viability of HeLa, PC12 and SH-SY5Y cells.
    AnnH31
  • HY-129464
    NO-711ME 127586-66-7 98%
    NO-711ME is a prodrug of NO-711. NO-711 is a potent and selective GABA uptake inhibitor.
    NO-711ME
  • HY-12962A
    NMDA-IN-1 dihydrochloride 1784252-90-9 98%
    NMDA-IN-1 dihydrochloride is a selective NMDA NR2B antagonist with a Ki of 0.85 nM; NR2B Ca2+ influx IC50 is 9.7 nM. NMDA-IN-1 dihydrochloride inhibits Glu/Gly stimulated Ca2+ flux in Ltk- cells expressing the hNR1a/NR2B with a IC50 of 9.7 nM. NMDA-IN-1 dihydrochloride has no activities on NR2A, NR2C, NR2D, hERG-channel and α1-adrenergic receptor. NMDA-IN-1 dihydrochloride shows excellent activity in the mechanical hyperalgesia assay in rats. NMDA-IN-1 dihydrochloride can be used for the study of stroke, Parkinson, and neuropathic pain.
    NMDA-IN-1 dihydrochloride
  • HY-129661
    AH 7959 763023-14-9 98%
    AH 7959 is an orally active N-substituted cyclohexyl methyl benzamide compound that has analgesic effects, the oral and subcutaneous ED50 of AH 7959 in mice is greater than 100 mg/kg.
    AH 7959
  • HY-129666
    NSC-65847 6949-15-1 98%
    NSC-65847 is a groundbreaking dual inhibitor targeting both viral neuraminidase and Streptococcus pneumoniae neuraminidase.
    NSC-65847
Cat. No. Product Name / Synonyms Application Reactivity